Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Ototoxicity × Radiotherapy × Clear all

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 218 Breast Neoplasms 193 Lung Neoplasms 182 Glioblastoma 177 Head and Neck Neoplasms 165 Prostatic Neoplasms 151 Squamous Cell Carcinoma of Head and Neck 135 Lymphoma 135 Rectal Neoplasms 120 Central Nervous System Neoplasms 104 Esophageal Neoplasms 103 Leukemia 97 Brain Neoplasms 89 Precursor Cell Lymphoblastic Leukemia-Lymphoma 83 Pancreatic Neoplasms 83 Gliosarcoma 80 Esophageal Squamous Cell Carcinoma 71 Lymphoma, Follicular 70 Neoplasms 69 Lymphoma, Large B-Cell, Diffuse 68 Uterine Cervical Neoplasms 67 Lymphoma, Non-Hodgkin 66 Hodgkin Disease 66 Sarcoma 65 Burkitt Lymphoma 59 Glioma 58 Colorectal Neoplasms 57 Leukemia, Lymphocytic, Chronic, B-Cell 56 Lymphoma, Large-Cell, Immunoblastic 52 Astrocytoma 52

Interventions

sodium thiosulfate 3 Cisplatin 3 tempol 1 ebselen 1 Vorinostat 1 Thioctic Acid 1 Surveys and Questionnaires 1 Sodium Chloride 1 Radiotherapy, Intensity-Modulated 1 Radiotherapy, Conformal 1 Radiotherapy 1 Radiosurgery 1 Pantoprazole 1 Methotrexate 1 Hydroxymethylglutaryl-CoA Reductase Inhibitors 1 Hyaluronic Acid 1 Hearing Tests 1 Drug Therapy 1 Dexamethasone 1 Chemotherapy, Adjuvant 1 Chemoradiotherapy 1 Audiometry 1 Atorvastatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06551857 2025-04-16

CaSPiN

Turku University Hospital

Ototoxicity, Neoplasms, Hearing Loss, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon ⚡